PE20201447A1 - Anticuerpos anti-componente de complemento y metodos de uso - Google Patents
Anticuerpos anti-componente de complemento y metodos de usoInfo
- Publication number
- PE20201447A1 PE20201447A1 PE2020001585A PE2020001585A PE20201447A1 PE 20201447 A1 PE20201447 A1 PE 20201447A1 PE 2020001585 A PE2020001585 A PE 2020001585A PE 2020001585 A PE2020001585 A PE 2020001585A PE 20201447 A1 PE20201447 A1 PE 20201447A1
- Authority
- PE
- Peru
- Prior art keywords
- hvr
- seq
- sequence
- methods
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
SE REFIERE A UN ANTICUERPO AISLADO QUE INHIBE LA INTERACCION ENTRE EL COMPLEJO C1q y C1r2s2 QUE TIENE UNA FUNCION DE DESPLAZAMIENTO TAL QUE EL ANTICUERPO SE UNE AL COMPLEJO C1qrs Y PROMUEVE LA DISOCIACION DE C1q DEL COMPLEJO C1qrs, EL CUAL COMPRENDE: I) LA SECUENCIA DE HVR-H1 DE SEC ID NO: 32, II) LA SECUENCIA DE HVR-H2 DE SEC ID NO: 33, III) LA SECUENCIA DE HVR-H3 DE SEC ID NO: 34, IV) LA SECUENCIA DE HVR-L1 DE SEC ID NO: 35, V) LA SECUENCIA DE HVR-L2 DE SEC ID NO: 36, Y VI) LA SECUENCIA DE HVR-L3 DE SEC ID NO: 37. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO, EL CUAL ES UTIL PARA MEJORAR EL ACLARAMIENTO O ELIMINACION DE C1s DEL PLASMA.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018077527 | 2018-04-13 | ||
| JP2018188770 | 2018-10-04 | ||
| PCT/JP2019/015919 WO2019198807A1 (en) | 2018-04-13 | 2019-04-12 | Anti-complement component antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201447A1 true PE20201447A1 (es) | 2020-12-10 |
Family
ID=68164028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001585A PE20201447A1 (es) | 2018-04-13 | 2019-04-12 | Anticuerpos anti-componente de complemento y metodos de uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210198347A1 (es) |
| EP (1) | EP3774892A4 (es) |
| JP (2) | JP7333789B2 (es) |
| KR (1) | KR20200143459A (es) |
| CN (1) | CN112313249A (es) |
| AU (1) | AU2019250403A1 (es) |
| BR (1) | BR112020018357A2 (es) |
| CA (1) | CA3094312A1 (es) |
| CL (2) | CL2020002610A1 (es) |
| CR (1) | CR20200542A (es) |
| IL (1) | IL277827A (es) |
| MA (1) | MA52248A (es) |
| MX (1) | MX2020010528A (es) |
| PE (1) | PE20201447A1 (es) |
| SG (1) | SG11202010125VA (es) |
| WO (1) | WO2019198807A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
| KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| EP3969475A4 (en) * | 2019-05-15 | 2023-04-26 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE, PHARMACEUTICAL COMPOSITION AND METHOD |
| AU2020368745A1 (en) * | 2019-10-16 | 2022-04-21 | Chugai Seiyaku Kabushiki Kaisha | An antibody, a pharmaceutical composition, and a method |
| WO2022031978A1 (en) * | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| US11958899B2 (en) | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| CN117327732A (zh) * | 2022-12-31 | 2024-01-02 | 义翘神州(泰州)科技有限公司 | 充分自裂解重组C1s蛋白的表达质粒组合、表达宿主细胞及表达方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4954326B2 (ja) | 2008-04-11 | 2012-06-13 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| HUP0900319A2 (en) * | 2009-05-25 | 2011-01-28 | Eotvos Lorand Tudomanyegyetem | New peptides, method of producing therof and use thereof |
| TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| NZ629473A (en) * | 2012-06-18 | 2017-02-24 | Univ Leicester | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders |
| EP2983710B1 (en) * | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| EP3215527A4 (en) * | 2014-11-05 | 2018-04-18 | Annexon, Inc. | Humanized anti-complement factor c1q antibodies and uses thereof |
| HUE061076T2 (hu) * | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Humanizált anti-C1s ellenanyagok alkalmazási eljárások |
| SG11201803703UA (en) * | 2015-11-24 | 2018-06-28 | Annexon Inc | Anti-complement factor c1q fab fragments and uses thereof |
-
2019
- 2019-04-12 MX MX2020010528A patent/MX2020010528A/es unknown
- 2019-04-12 US US17/046,395 patent/US20210198347A1/en not_active Abandoned
- 2019-04-12 CA CA3094312A patent/CA3094312A1/en active Pending
- 2019-04-12 MA MA052248A patent/MA52248A/fr unknown
- 2019-04-12 JP JP2020555924A patent/JP7333789B2/ja active Active
- 2019-04-12 PE PE2020001585A patent/PE20201447A1/es unknown
- 2019-04-12 CN CN201980038684.5A patent/CN112313249A/zh active Pending
- 2019-04-12 CR CR20200542A patent/CR20200542A/es unknown
- 2019-04-12 AU AU2019250403A patent/AU2019250403A1/en active Pending
- 2019-04-12 KR KR1020207032744A patent/KR20200143459A/ko unknown
- 2019-04-12 EP EP19784866.6A patent/EP3774892A4/en active Pending
- 2019-04-12 SG SG11202010125VA patent/SG11202010125VA/en unknown
- 2019-04-12 BR BR112020018357-1A patent/BR112020018357A2/pt unknown
- 2019-04-12 WO PCT/JP2019/015919 patent/WO2019198807A1/en active Application Filing
-
2020
- 2020-10-06 IL IL277827A patent/IL277827A/en unknown
- 2020-10-09 CL CL2020002610A patent/CL2020002610A1/es unknown
-
2023
- 2023-06-16 CL CL2023001793A patent/CL2023001793A1/es unknown
- 2023-08-15 JP JP2023132187A patent/JP2023154049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL277827A (en) | 2020-11-30 |
| AU2019250403A1 (en) | 2020-11-19 |
| CR20200542A (es) | 2021-01-18 |
| JP2023154049A (ja) | 2023-10-18 |
| SG11202010125VA (en) | 2020-11-27 |
| BR112020018357A2 (pt) | 2020-12-29 |
| EP3774892A4 (en) | 2022-02-16 |
| US20210198347A1 (en) | 2021-07-01 |
| CN112313249A (zh) | 2021-02-02 |
| CL2023001793A1 (es) | 2023-12-15 |
| KR20200143459A (ko) | 2020-12-23 |
| EP3774892A1 (en) | 2021-02-17 |
| MA52248A (fr) | 2021-02-17 |
| CL2020002610A1 (es) | 2021-02-12 |
| CA3094312A1 (en) | 2019-10-17 |
| MX2020010528A (es) | 2020-11-06 |
| WO2019198807A1 (en) | 2019-10-17 |
| JP7333789B2 (ja) | 2023-08-25 |
| JP2021521206A (ja) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201447A1 (es) | Anticuerpos anti-componente de complemento y metodos de uso | |
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| AR091701A1 (es) | Anticuerpos anti-cd22 e inmunoconjugados | |
| PE20141722A1 (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| AR099855A1 (es) | Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso | |
| PE20091318A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos | |
| PE20150211A1 (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| PE20170935A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| PE20181402A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
| PE20181009A1 (es) | ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS | |
| PE20090943A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| AR098743A1 (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| PE20170125A1 (es) | Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t | |
| PE20140995A1 (es) | Agonistas de fgfr1 y sus metodos de uso | |
| PE20141693A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek | |
| MX2017005987A (es) | Anticuerpos anti-interleucina(il)-1beta y metodos de uso. | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| PE20190733A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y metodos de uso |